GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Immatics N.V.
Immatics is a biotech company developing cutting-edge T-cell immunotherapy for cancer. Its stock price is a venture bet on the success of its complex scientific platform. The stock price reflects high volatility, dependence on lab news and partnerships with big pharma.
Share prices of companies in the market segment - Oncology immuno-therapy
Immatics N.V. is a biotech company developing cutting-edge T-cell receptor-based cancer immunotherapies. We've categorized it as an "Immuno-Oncology" company, and the chart below shows how investors view the prospects of this breakthrough, yet high-risk, medical field.
Broad Market Index - GURU.Markets
Immatics N.V. is a biotech company developing cutting-edge T-cell receptor-based cancer immunotherapy. Its innovativeness earns it a spot in the GURU.Markets index. The chart below compares its performance, reflecting investor expectations, with the overall market picture.
Change in the price of a company, segment, and market as a whole per day
IMTX - Daily change in the company's share price Immatics N.V.
Shares of Immatics, an oncology company, are extremely volatile. Change_co measures market reaction to clinical trial data in cell therapy. This metric is an essential component for building valuation models for companies at the forefront of immuno-oncology on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Oncology immuno-therapy
Immatics N.V. is an oncology company. This chart highlights the extreme volatility of the biotech sector. Comparison with IMTX's performance, which hinges on the results of clinical trials for its immunotherapy platform, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Immatics is a biopharmaceutical company pioneering the development of T-cell therapy for cancer treatment. Immuno-oncology is a highly volatile and rapidly growing sector. The chart below reflects the average fluctuations in this field, helping to assess the risks and performance of Immatics stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Immatics N.V.
Immatics is a biotech company developing cancer immunotherapy drugs. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Annual dynamics of market capitalization of the market segment - Oncology immuno-therapy
Immatics N.V. is a biotech company pioneering the development of T-cell therapy for cancer treatment. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential of its scientific platform and the high risks inherent in this sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Immatics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new cancer immunotherapy trials. The company's chart exists in a world of its own, where data releases are the key events.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Immatics N.V.
Ryerson, one of North America's largest metal distributors, displays monthly fluctuations on the chart as a barometer for the entire industry. They reflect metal prices and demand from the manufacturing sector, the primary consumer of its products.
Monthly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Immatics N.V. is a biotech company developing cutting-edge cancer immunotherapy. This sector is at the forefront of medical innovation, but is fraught with extreme risks. The chart below reflects overall investor sentiment in the oncology immunotherapy segment, which can change dramatically following news of clinical trial successes or failures.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Immatics develops cutting-edge cancer immunotherapy methods. It is a company at the forefront of science. Its value lies in its intellectual property and the potential of its clinical developments. Its stock performance is driven by scientific breakthroughs and partnerships, not by general economic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Immatics N.V.
Immatics develops immunotherapy for cancer treatment. The company's weekly stock price is a classic example of a highly volatile biotech, where prices react sharply to the release of clinical trial data and partnership news.
Weekly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Immatics is a biotech company developing immunotherapy. Comparing its weekly performance to the broader biotech sector only highlights its uniqueness. The chart shows how news about clinical trials of its cutting-edge approaches drives share price movements independent of overall trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Immatics, a biotech company, exist in a world of their own, far removed from macroeconomic news. Their performance is driven by clinical trial data. A comparison chart with the S&P 500 clearly demonstrates how the stock can move regardless of the broader market.
Market capitalization of the company, segment and market as a whole
IMTX - Market capitalization of the company Immatics N.V.
Immatics' market capitalization chart tells the story of cutting-edge immuno-oncology technology. The company is developing T-cell therapy to fight cancer. Its volatile chart reflects investors' faith in its scientific platform and early clinical trial data. It's a visualization of a risky but potentially revolutionary bet on the future of cancer treatment.
IMTX - Share of the company's market capitalization Immatics N.V. within the market segment - Oncology immuno-therapy
Immatics is a biotech company developing cutting-edge T-cell immunotherapy for cancer treatment. Its market share reflects investors' faith in its innovative approaches to cancer treatment. The chart below illustrates expectations for the next generation of cancer therapies being developed by Immatics.
Market capitalization of the market segment - Oncology immuno-therapy
Immatics develops T-cell receptor-based cancer immunotherapies, creating personalized treatments. The chart below shows the overall market capitalization of the immuno-oncology sector. Its dynamics reflect the enormous expectations and investment in this cutting-edge field of medicine, where Immatics is a technological leader.
Market capitalization of all companies included in a broad market index - GURU.Markets
This shows the front lines of the fight against cancer. Immatics is developing cell therapies that "train" immune cells to attack tumors. Its volatile line reflects the scientific breakthroughs and setbacks in this complex field. It's a visualization of the hope that our own immunity will become the primary weapon against cancer.
Book value capitalization of the company, segment and market as a whole
IMTX - Book value capitalization of the company Immatics N.V.
Immatics' foundation is its scientific platforms for discovering and developing T-cell receptors for cancer immunotherapy and its cell therapy manufacturing capabilities. This represents cutting-edge scientific and technological capital. The chart shows how this biotech company is building its capital base to fund its breakthrough research.
IMTX - Share of the company's book capitalization Immatics N.V. within the market segment - Oncology immuno-therapy
Immatics develops cutting-edge cancer immunotherapy methods. Its strength lies in its unique scientific platforms and in-house cell therapy capabilities. The chart shows the company's share of the complex and expensive physical infrastructure required to create personalized cancer drugs.
Market segment balance sheet capitalization - Oncology immuno-therapy
Developing immunotherapy like Immatics' is a knowledge-intensive and potentially capital-intensive business. Compared to its pharmaceutical sector assets, its advanced platform requires sophisticated laboratories, and commercialization will also require manufacturing capacity.
Book value of all companies included in the broad market index - GURU.Markets
Immatics' book value is derived from its cutting-edge laboratories and manufacturing facilities in Germany and the US, specializing in the development of T-cell immunotherapies for cancer. The company's assets reflect its technology platform for target identification and the development of personalized drugs. The chart shows the physical weight of this biotech company.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Immatics N.V.
Immatics, a pioneer in T-cell therapy, is valued by the market at multiples of its lab value. Investors are paying for its unique scientific platform, capable of identifying new targets for attacking cancer tumors, and its pipeline of promising developments.
Market to book capitalization ratio in a market segment - Oncology immuno-therapy
Immatics is a biotech company developing cutting-edge cancer immunotherapy. Its value lies in its scientific platform. This chart shows the enormous premium investors are paying for its potential to create breakthrough treatments, valuing the company far above its tangible assets.
Market to book capitalization ratio for the market as a whole
Immatics is a biotech company developing cutting-edge cancer immunotherapy methods. Its scientific platform is aimed at creating personalized T-cell therapies. The company's market valuation is based entirely on its belief in its scientific approach. This metric demonstrates how valuation in cutting-edge biotech can be divorced from traditional financial metrics.
Debts of the company, segment and market as a whole
IMTX - Company debts Immatics N.V.
Immatics, a biotech company developing cancer immunotherapies, funds its cutting-edge but very expensive research through partnerships and capital raising, including debt. This chart shows how the company is investing in building a platform for developing personalized cancer treatments, which requires significant upfront costs.
Market segment debts - Oncology immuno-therapy
Immatics is a biotech company developing immunotherapeutic approaches for cancer treatment, including CAR-T cell therapy. This is one of the most advanced and expensive areas in medicine. This chart shows how the company funds its complex research and clinical trials, raising significant capital to realize its ambitious goals.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Immatics N.V.
Immatics develops cutting-edge cancer immunotherapy methods, including CAR-T cell therapy. This is one of the most research- and capital-intensive areas in modern medicine. This chart shows how the company uses debt to finance its breakthrough, but very expensive, research and clinical trials, reflecting the high financial risks.
Market segment debt to market segment book capitalization - Oncology immuno-therapy
Immatics is a biotech company working at the forefront of immuno-oncology, developing T-cell therapies for cancer. This is an extremely complex and expensive field. This chart shows how the company finances its cutting-edge research, comparing its debt structure to the overall financial landscape of the biotech sector.
Debt to book value of all companies in the market
Immatics develops cutting-edge cancer immunotherapy. Developing such complex and personalized drugs is a lengthy and extremely expensive process. Does the company finance its breakthrough research with debt? This chart of total market debt provides context for assessing the riskiness of its financial model in the biotech sector.
P/E of the company, segment and market as a whole
P/E - Immatics N.V.
Immatics is a biotech company developing immunotherapeutic drugs for cancer treatment. This chart reflects the high expectations for its innovative approaches to fighting cancer. The volatile valuation reflects both the potential breakthroughs and the risks inherent in biotech developments.
P/E of the market segment - Oncology immuno-therapy
Immatics develops cutting-edge T-cell immunotherapy methods for the treatment of oncology. The company creates both proprietary and adapted cell therapies to combat cancer. This chart shows the average market value for the immuno-oncology sector, helping to understand the market premium placed on Immatics' innovative and complex technologies.
P/E of the market as a whole
Immatics is a biotech company developing cutting-edge cancer immunotherapy. This is an extremely complex and competitive field. Does the company's valuation reflect the general investor appetite for risky biotech assets, or is it a unique bet on its scientific platform and partnerships with major pharmaceutical companies that could deliver results regardless of the market?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Immatics N.V.
Immatics is a biotech company developing T-cell-based cancer immunotherapies. Its technologies are aimed at creating personalized treatments. This chart reflects investors' confidence in the scientific breakthrough and commercial potential of its platform. Future profits depend on the success of clinical trials and partnerships with pharma giants.
%20P%2FE%20Immatics%20N.V.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Immatics-N.V.&v=1772646473202 "Chart of the company's future (projected) P/E Immatics N.V.")
Future (projected) P/E of the market segment - Oncology immuno-therapy
Immatics develops cutting-edge T-cell immunotherapy for cancer treatment. The company's technologies are aimed at creating personalized drugs that recognize and destroy tumor cells. The graph shows expectations across the oncology industry, allowing market confidence in Immatics' innovative platform to be compared with those of its competitors.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-immuno-therapy&v=1772646473212 "Future (projected) P/E graph of the market segment - Oncology immuno-therapy")
Future (projected) P/E of the market as a whole
Immatics N.V. is a biotech company developing cancer immunotherapy, one of the most advanced fields in medicine. The company's valuation is based on expectations of future breakthroughs. This chart of overall market sentiment shows how willing investors are to fund capital-intensive scientific research with a long-term horizon.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772646473230 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Immatics N.V.
Immatics develops cutting-edge cancer immunotherapy methods using T-cell receptors. The company is at the forefront of science, and its financial results represent a net loss due to massive investments in R&D. This chart illustrates the high cost of developing breakthrough oncology drugs and the long journey from the lab to the patient.
Profit of companies in the market segment - Oncology immuno-therapy
Immatics develops cutting-edge cancer immunotherapy methods using T-cell receptors to combat tumors. This chart, reflecting the biotech sector's profitability, is an indicator of the investment climate. For a company at the forefront of science, it shows the market's willingness to fund complex, long-term research that impacts patients' lives.
Overall market profit
Immatics N.V. is developing cutting-edge cancer immunotherapy methods using T-cell receptors. This is one of the most promising, but also capital-intensive, areas of medicine. The overall growth in corporate profits, reflected in this chart, creates a favorable investment climate. During such periods, investors are more willing to invest in high-risk, high-potential biotech companies.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Immatics N.V.
Immatics develops cutting-edge cancer immunotherapy approaches using T-cell receptor (TCR) technologies to combat solid tumors. The company's future depends on the success of its clinical programs. This chart summarizes analyst opinions on the likelihood of breakthroughs in cancer treatment and the future commercial potential of its innovative cell therapies.
%20profit%20of%20the%20company%20Immatics%20N.V.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Immatics-N.V.&v=1772646473255 "Graph of future (projected) profit of the company Immatics N.V.")
Future (predicted) profit of companies in the market segment - Oncology immuno-therapy
Immatics N.V. is a biotechnology company developing cutting-edge T-cell immunotherapies for cancer treatment. Its future is tied to the success of its innovative platform and clinical programs. This chart, which charts oncology sector forecasts, demonstrates the investor confidence in the commercial potential of new approaches to fighting cancer, which is critical for Immatics.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-immuno-therapy&v=1772646473263 "Graph of future (predicted) profits of companies in a market segment - Oncology immuno-therapy")
Future (predicted) profit of the market as a whole
Immatics develops cutting-edge cancer immunotherapy methods. The company's success depends on scientific breakthroughs, not GDP. However, the overall market profit forecast presented here reflects the overall investment climate. Positive expectations facilitate raising the capital needed for expensive clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772646473291 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Immatics N.V.
Immatics N.V. is a biotech company developing cutting-edge cancer immunotherapy. Since the company is in the research stage, this chart is crucial. It shows the significant premium investors are paying for the potential of its scientific platforms when assessing future revenues from a potential breakthrough in cancer treatment.
P/S market segment - Oncology immuno-therapy
Immatics develops cutting-edge T-cell immunotherapy to combat cancer. The company is in the clinical stage, and its valuation is determined by the potential of its scientific platform and future commercial prospects. This chart reflects the average valuation in the sector, helping to understand how high investor expectations are for Immatics' innovative approach.
P/S of the market as a whole
Immatics is a biotech company developing innovative T-cell immunotherapy methods for cancer treatment. Its research is aimed at creating personalized drugs. This chart, which reflects revenue estimates for traditional companies, clearly demonstrates the enormous premium investors are willing to pay for cutting-edge scientific technologies that could revolutionize cancer treatment.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Immatics N.V.
Immatics is a biotech company developing cutting-edge cancer immunotherapy methods. Its research aims to train a patient's immune system to fight tumors. This chart reflects investors' faith in the breakthrough potential of its scientific platform, which could lead to the creation of highly effective drugs in the future.
%20P%2FS%20Immatics%20N.V.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Immatics-N.V.&v=1772646473316 "The graph of the company's future (projected) P/S Immatics N.V.")
Future (projected) P/S of the market segment - Oncology immuno-therapy
Immatics N.V. is a biotechnology company developing innovative T-cell immunotherapies for the treatment of oncology. The company's technologies are aimed at creating personalized cancer treatments. This chart reflects average revenue expectations in the immuno-oncology sector, allowing us to assess how the market perceives Immatics' breakthrough potential.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-immuno-therapy&v=1772646473330 "Future (projected) P/S market segment graph - Oncology immuno-therapy")
Future (projected) P/S of the market as a whole
Immatics N.V. develops cutting-edge cancer immunotherapy methods by "training" a patient's own T cells to recognize and attack tumors. This indicator reflects the market's collective expectations. Immatics' progress in clinical trials fuels hopes for a revolution in oncology, which is one of the most powerful drivers of investor optimism in the biotech sector.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772646473342 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Immatics N.V.
This chart illustrates the revenue of Immatics N.V., a biopharmaceutical company developing advanced T-cell immunotherapy for cancer treatment. Currently, its revenue is generated primarily through strategic partnerships with major pharmaceutical companies. The dynamics reflect the success of its scientific platform and progress in clinical development.
Sales of companies in the market segment - Oncology immuno-therapy
Immatics N.V. is a biotechnology company developing innovative T-cell immunotherapy methods for cancer treatment. This chart reflects the growth of the oncology market. Immatics's cutting-edge approaches targeting difficult-to-treat tumors could lead to breakthroughs in treatment and significantly expand the capabilities and, consequently, the size of the entire immuno-oncology segment.
Overall market sales
Immatics N.V. is a biotechnology company developing immunotherapeutic cancer treatments. Its growth requires significant investment in research. This total revenue chart reflects the state of the economy, which influences investors' risk appetite and their willingness to fund cutting-edge scientific research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Immatics N.V.
Immatics develops cutting-edge cancer immunotherapy methods. For a company in clinical development, this graph reflects future revenue potential, not current revenue. It illustrates analysts' confidence in the success of its scientific platforms and the commercial potential of cell therapy.
%20sales%20of%20the%20company%20Immatics%20N.V.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Immatics-N.V.&v=1772646473358 "Schedule of future (projected) sales of the company Immatics N.V.")
Future (projected) sales of companies in the market segment - Oncology immuno-therapy
Immatics develops cutting-edge T-cell immunotherapy methods to combat cancer. The company uses proprietary platforms to identify tumor targets and create potent cell-based products. This chart shows the forecast for the entire immuno-oncology market, one of the fastest-growing and most innovative segments of biopharma, where Immatics is a leader.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-immuno-therapy&v=1772646473373 "Schedule of future (projected) sales of companies in the market segment - Oncology immuno-therapy")
Future (projected) sales of the market as a whole
Immatics N.V. develops cutting-edge cancer immunotherapy. The company is at the forefront of science, and its funding depends on investors' risk appetite and faith in new technologies. This chart reflects the overall investment climate, which determines the availability of capital for long-term, capital-intensive biotech projects with the potential to revolutionize medicine.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772646473376 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Immatics N.V.
Immatics develops cutting-edge T-cell immunotherapy to fight cancer. It's a science-intensive business, requiring massive investments in research. This chart reflects the company's operating losses—the price it pays to develop personalized cancer treatments. This is an investment in a future where the immune system will become the primary weapon against disease.
Market segment marginality - Oncology immuno-therapy
Immatics is a biotech company developing innovative T-cell immunotherapy approaches for cancer treatment. Profitability is a long-term goal. This chart reflects significant investments in research and clinical trials of their cutting-edge platforms. Investors analyze it to assess the company's potential to develop next-generation cancer therapies.
Market marginality as a whole
Immatics is a biotech company developing cancer immunotherapies that target cancer proteins inside cells that were previously thought to be inaccessible. They are at the cutting edge of oncology. This graph, reflecting the state of the economy, is secondary to them. The success of their breakthrough technology could create a multi-billion dollar market, regardless of general business cycles.
Employees in the company, segment and market as a whole
Number of employees in the company Immatics N.V.
Immatics is a biotech company developing T-cell-based immunotherapies for cancer treatment. Its team is a combination of research scientists and specialists in the production of complex cellular products. Growth on this chart represents progress in research and expansion of manufacturing capacity.
Share of the company's employees Immatics N.V. within the market segment - Oncology immuno-therapy
Immatics develops cutting-edge immunotherapeutic methods for cancer treatment using proprietary cell-targeting technologies. This chart reflects the company's growing scientific talent in this complex area of oncology. This growth is directly related to the expansion of its research programs and the advancement of candidates in clinical trials.
Number of employees in the market segment - Oncology immuno-therapy
Immatics N.V. is a clinical-stage biopharmaceutical company developing T-cell immunotherapy for cancer. This chart shows the employment dynamics in one of the most advanced areas of oncology. The growing number of scientists and clinical trial specialists in this field reflects the enormous investment and hopes associated with the development of personalized cancer treatments.
Number of employees in the market as a whole
Immatics is a biotech company developing cutting-edge cancer immunotherapy. Its technologies are designed to "teach" a patient's immune system to recognize and attack cancer cells. This figure demonstrates how Immatics' breakthroughs in immuno-oncology are creating high-tech jobs and shaping the future of medicine.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Immatics N.V. (IMTX)
Immatics N.V. is a biotech company developing T-cell immunotherapy for cancer. This chart is a classic example of intellectual capital valuation. The market values not its staff, but the potential of its sophisticated scientific platform to develop new treatments. The chart demonstrates the high future value that investors attribute to the research and development efforts of each of the company's scientists.
%20of%20the%20company%20Immatics%20N.V.%20(IMTX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Immatics-N.V.-IMTX&v=1772646473448 "Chart of market capitalization per employee (in thousands of dollars) of the company Immatics N.V. (IMTX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Immatics develops cutting-edge cancer immunotherapy methods. Like many biotech companies, its value is driven by its unique scientific platform and clinical development potential. This chart shows the company's extremely high intellectual property market valuation per employee, reflecting the high expectations for its technology.
%20by%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-immuno-therapy&v=1772646473451 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology immuno-therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Immatics is a biotech company developing immunotherapeutic drugs for cancer treatment. The chart reflects the valuation of its cutting-edge scientific platform. The company's entire value lies in its intellectual property and potential to create a new class of drugs. This metric demonstrates the enormous value the market places on the work of each scientist.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772646473457 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Immatics N.V. (IMTX)
Immatics is a biotech company developing cutting-edge T-cell immunotherapy for cancer treatment. This is one of the most complex and expensive areas of R&D. This chart illustrates the cost of cutting-edge science: the enormous investment required for each highly qualified scientist working on personalized cancer treatments.
%20Chart%20Immatics%20N.V.%20(IMTX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Immatics-N.V.-IMTX&v=1772646473458 "Company Profit Per Employee (in thousands of dollars) Chart Immatics N.V. (IMTX)")
Profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Immatics (IMTX) is a German biotech company developing cutting-edge T-cell immunotherapy for cancer. This is a clinical-stage, deep-science company. This metric (loss per employee) reflects the massive investment in R&D and a world-class team of scientists to create this platform.
%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-immuno-therapy&v=1772646473458 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Immatics N.V. is a biotech company developing a new class of cell therapies (TCR-T) and antibodies for the treatment of oncology. This is an R&D business. The company is not profitable. This chart shows the capital burn rate: the operating loss per team of scientists developing this complex therapy.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772646473460 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Immatics N.V. (IMTX)
Immatics develops immunotherapeutic approaches for cancer treatment. This chart reflects the financial returns from its sophisticated scientific platform. During clinical trials, revenue is generated primarily through collaborations with large pharmaceutical companies, and the growth in revenue per employee demonstrates recognition of the value of their technologies.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Immatics-N.V.-IMTX&v=1772646473462 "Sales chart per company employee Immatics N.V. (IMTX)")
Sales per employee in the market segment - Oncology immuno-therapy
Immatics develops cutting-edge cancer immunotherapy (TCR-T). This chart shows how productive their team of top-tier scientists is. It measures revenue (often from partnerships with big pharma) per employee, a key indicator of the effectiveness of their R&D platform compared to other companies in the segment.
Sales per employee for the market as a whole
Immatics (IMTX) is a biotech company developing cutting-edge cancer immunotherapy (TCR-based therapies). Being in the clinical stage, the company generates revenue primarily from partnerships and collaborations rather than product sales. This chart shows how effectively the company's elite scientific staff converts its R&D services and developments into partner revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Immatics N.V. (IMTX)
Immatics N.V. is a biotech company developing T-cell immunotherapy for cancer. This is one of the most advanced, but also risky, areas in oncology. This chart reflects the bearish bets of investors who doubt the efficacy or safety of its platform and expect failure in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Immatics-N.V.-IMTX&v=1772646473475 "Short Shares Chart for the Company Immatics N.V. (IMTX)")
Shares shorted by market segment - Oncology immuno-therapy
Immatics N.V. is a biotech company developing T-cell immunotherapy (CAR-T, TCR) for cancer treatment. This chart shows bearish sentiment. The "shorts" here are betting that their highly complex and personalized therapy will not prove effective or safe in the clinic.
Shares shorted by the overall market
Immatics is developing cutting-edge cancer immunotherapy. This is an extremely complex and expensive science. When the level of fear rises on this chart, investors lose faith in the long-term prospects. Biotech funding dries up, and the "race against time" for companies like IMTX becomes not only scientific but also financial.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Immatics N.V. (IMTX)
Immatics is a biotech company developing TCR-based therapies (immuno-oncology). The stock is volatile and dependent on R&D. A chart reading above 70 may reflect positive trial or partnership data. Oversold levels (<30) are often associated with research setbacks or a general decline in biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Immatics-N.V.-IMTX&v=1772646473498 "RSI 14 indicator chart for the company's stock Immatics N.V. (IMTX)")
RSI 14 Market Segment - Oncology immuno-therapy
Immatics (IMTX) is a German biotech company and a T-cell "guru." Their platform (XCEPTOR) "trains" the immune system to attack intracellular cancer targets. RSI_14_Seg for "Oncology" (biotech) shows the overall sentiment. It helps us understand whether IMTX's volatility reflects their breakthrough platform or the general hype in the sector.
RSI 14 for the overall market
Immatics (IMTX) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast IMTX (Immatics N.V.)
Immatics N.V. (IMTX) is a biotech company developing T-cell receptor (TCR)-based cancer immunotherapies. Its platform targets difficult-to-reach cancer targets. This chart reflects analyst consensus. Their price targets are based on estimates of the potential of this complex technology and early clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-IMTX-Immatics-N.V.&v=1772646473527 "A chart showing analyst consensus forecasts for the expected stock price. IMTX (Immatics N.V.)")
The difference between the consensus estimate and the actual stock price IMTX (Immatics N.V.)
Immatics (IMTX) is a German biotech developing advanced T-cell therapy (TCR) for the treatment of solid tumors. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high potential analysts see in their complex but promising oncology platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-IMTX-Immatics-N.V.&v=1772646473531 "A chart showing the difference between the consensus forecast and the actual stock price. IMTX (Immatics N.V.)")
Analyst consensus forecast for stock prices by market segment - Oncology immuno-therapy
Immatics (IMTX) is a German biotech company and a pioneer in T-cell therapy. It develops "living drugs" (TCR-T) to attack solid tumors. This chart shows general expectations for the immunotherapy sector. It reflects whether experts believe cell therapy will achieve breakthroughs in the treatment of solid cancers.
Analysts' consensus forecast for the overall market share price
Immatics (IMTX) is a German biotech company working at the forefront of immuno-oncology. They are developing live drugs (TCR-T) and antibodies targeting cancer cells. This chart shows the overall risk appetite of Immatics. It reflects the willingness of investors to fund breakthrough but high-risk scientific platforms for cancer treatment.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Immatics N.V.
Immatics is a German biotech company working at the forefront of immuno-oncology. They develop T-cell therapies (TCRs) that train the immune system to attack specific cancer tumors. This chart represents a pure R&D bet. It likely reflects the market's confidence in their sophisticated scientific platform, their alliances with pharma giants, and their early clinical data.
AKIMA Market Segment Index - Oncology immuno-therapy
Immatics (IMTX) is a German biotech pioneer in cancer immunotherapy; the company is developing two platforms: TCR-T (cell therapy) and bispecific antibodies (TCER) for the treatment of solid tumors. This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this breakthrough (TCR) R&D platform (IMTX) differentiate it from the average pharma company?
The AKIM Index for the overall market
Immatics is a biotech company developing T-cell immunotherapies for cancer treatment. The company focuses on identifying new tumor targets. This market average chart provides a macro backdrop. It helps assess how this innovative oncology platform compares to the broader economic trends affecting biotech.
